I definitely understand the need for further trials and a larger dataset, especially with a treatment that's in its infancy for treating mental disorders. Looking at what mindmed and compass are doing, it seems very promising. However, the road to commercialization is very different and I appreciate your insights.
Averaging down on a dying company. Yes that does seem silly. Although buying in at sub 2c to see it rise back up to 4c after the 17m shares have been dropped would help. I've followed CPH for about 1.5 years and it sure seems a mess. I'm curious if it'll change with the recent switch outs etc. Even if to 10c and I'll happily take a 30% profit at that stage, IF it gets to that again ..
CPH Price at posting:
3.1¢ Sentiment: Hold Disclosure: Held